Minhang Xin

Key Laboratory Of Environment And Genes Related To Diseases
Xi'an, 710061, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Synthesis and degradation effect of PROTACs targeting EGFR triple mutants.

Synthesis and degradation effect of PROTACs targeting EGFR triple mutants.

Journal: Bioorganic & medicinal chemistry

Published: August 19, 2025

Lysine-Targeted Covalent Strategy Leading to the Discovery of Novel Potent PROTAC-Based PI3Kδ Degraders.

Lysine-Targeted Covalent Strategy Leading to the Discovery of Novel Potent PROTAC-Based PI3Kδ Degraders.

Journal: Journal of medicinal chemistry

Published: May 31, 2025

Discovery of novel covalent PI3Kδ inhibitors bearing alaninamide moiety by lysine-targeted covalent strategy.

Discovery of novel covalent PI3Kδ inhibitors bearing alaninamide moiety by lysine-targeted covalent strategy.

Journal: European journal of medicinal chemistry

Published: May 09, 2025

Lysine-Targeted Covalent Inhibitors of PI3Kδ Synthesis and Screening by In Situ Interaction Upgradation.

Lysine-Targeted Covalent Inhibitors of PI3Kδ Synthesis and Screening by In Situ Interaction Upgradation.

Journal: Journal of medicinal chemistry

Published: November 19, 2024

Menin-MLL protein-protein interaction inhibitors: a patent review (2021-present).

Menin-MLL protein-protein interaction inhibitors: a patent review (2021-present).

Journal: Expert opinion on therapeutic patents

Published: October 25, 2024

Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality.

Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality.

Journal: Science advances

Published: March 29, 2024

Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors.

Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors.

Journal: European journal of medicinal chemistry

Published: January 02, 2024

Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors.

Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors.

Journal: European journal of medicinal chemistry

Published: August 29, 2023

Design, synthesis and biological evaluation of novel selective PI3Kδ inhibitors containing pyridopyrimidine scaffold.

Design, synthesis and biological evaluation of novel selective PI3Kδ inhibitors containing pyridopyrimidine scaffold.

Journal: Future medicinal chemistry

Published: August 11, 2023

Design, synthesis and bioactivity evaluation of selenium-containing PI3Kδ inhibitors.

Design, synthesis and bioactivity evaluation of selenium-containing PI3Kδ inhibitors.

Journal: Bioorganic chemistry

Published: July 17, 2023

Discovery of novel pyrido[3,2-d]pyrimidine derivatives as selective and potent PI3Kδ inhibitors.

Discovery of novel pyrido[3,2-d]pyrimidine derivatives as selective and potent PI3Kδ inhibitors.

Journal: Drug development research

Published: June 22, 2023

Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments.

Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments.

Journal: Bioorganic chemistry

Published: January 16, 2023

Showing 1-12 of 61

Last Updated: 09/26/2026